CytoDyn Closes $17.5M Financing to Fund Continued Development of Leronlimab

CytoDyn has raised $17.5M to support the continued clinical development of its investigational antibody leronlimab. The financing, with Paulson Investment Company serving as placement agent, will fund ongoing trials, regulatory activities, and operations as the company advances programs in cancers including triple-negative breast cancer and metastatic colorectal cancer.